MEDPRIN is committed to industrialization of series of international leading regenerative medicine engineering technology in China. MEDPRIN’s first product ReDura® Biomimetic-Synthetic-Absorbable Dural Substitute has accepted CE and CFDA registration certificate. ReDura® has been widely applied in more than 60 countries on tens of thousands of cases, and thus is considered as the dura mater (ridge) membrane closest to patient’s autologous cells with the best repair effect. In order to further develop the product market, MEDPRIN has been actively executing strategy of globalization, and has set up branches respectively in America, Germany and China, providing market and technical support to customers around the world.
In addition to ReDura®, MEDPRIN is doing the endeavor to develop a dozen of human tissue repair products, including personalized skull and maxillofacial repair system, female pelvic diaphragm repair system, tensionless urethral sling, hernia repair piece, artificial skin, blood vessels and ligament, laying technical foundation for future development of more complex and advanced artificial tissues and organs. MEDPRIN will make great efforts for continuous innovation, embracing the objective to become the world's leading high-end implantable medical device company that can make considerable contribution to the improvement of Chinese technology and industrialization of medical devices.